

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**YSB Inc.**

**藥師幫股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9885)**

**VOLUNTARY ANNOUNCEMENT  
ENTERING INTO OF A STRATEGIC COOPERATION  
AND BUSINESS DEPLOYMENT AGREEMENT**

This announcement is made by YSB Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors about the latest development of certain business of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on 3 June 2025, the Group entered into a strategic cooperation and business deployment agreement (the “**Strategic Agreement**”) with SHENZHEN DOBOT CORP LTD (the H shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited; stock code: 2432. HK) (“**DOBOT**”), pursuant to which a close strategic cooperation was initiated, together with the commencement of concrete project deployments.

**BACKGROUND OF THE COOPERATION**

Founded in 2015, the Group has been dedicated to the outside-of-hospital pharmaceutical market and primary healthcare sector since its establishment. It strives to empower a wide range of enterprises in the upstream and downstream of the pharmaceutical industry, and deliver digital and intelligent solutions to monomer pharmacies and chain pharmacies as well as primary healthcare institutions. Also founded in 2015, leveraging its proprietary full-stack cobot development technologies, DOBOT has launched over 20 cobots to cater to the needs in various scenarios such as medical and healthcare, automotive, semiconductor, chemical and new retail, solidifying its position as an industry benchmark.

According to an industry report issued by China Insights Industry Consultancy Limited, the global cobot market for the medical and healthcare sector is expected to reach US\$373.2 million in 2028. The Group also expects the robot market to continue to grow significantly, with the medical and healthcare sector becoming an important scenario for the application and promotion of cobots.

## **SUMMARY OF STRATEGIC AGREEMENT**

Based on their long-standing industry leadership and highly synergistic business ecosystems, the parties have decided to establish a comprehensive strategic cooperation partnership to jointly explore the application of cobots and related AI products in the fields of pharmaceutical R&D, warehousing, delivery, real-time retailing and medication services by focusing on the core technologies of pharmaceutical cobots, pharmaceutical AI large models and the IoT of pharmaceuticals, with a view to promoting the integration and upgrading of robotics and pharmaceutical industry and achieving the Group's mission of "To make quality medical care and good medicine accessible to all (讓好醫好藥普惠可及)" and DOBOT's vision of "Realise optimal human-machine collaboration (實現人機協作的最優配置)".

## **UPDATE ON BUSINESS DEPLOYMENT PROGRESS**

At the initial stage of the strategic cooperation, both parties will commence cooperation in the field of pharmacies and pharmaceutical warehousing cobots. Currently, both parties have finalised the plan for the first landing project, and have completed the feasibility study, technical route research and judgement, exchange of technical solutions, and selection of suitable deployment environment, and have begun to build a test platform.

Both parties will follow the principles of collaborative innovation and win-win development in the cooperation, and share technical materials as well as newly generated intellectual property rights and business secrets during the cooperation. Under the terms of the agreement, DOBOT shall have the exclusive right to produce the robots of this project whilst the Group shall have the exclusive right to sell the same in the pharmaceutical industry. Based on this project and leveraging their respective strengths, both parties will continue to embark on more new projects under the framework of the Strategic Agreement.

The Board of the Group believes that the establishment of the strategic cooperation relationship with DOBOT is conducive to the integration of resources and collaborative innovation, so as to make full use of the industry-leading advantages of both parties to promote industrial technology development and enhance the health and well-being of the society.

## **GENERAL**

To the best knowledge and information of the Board, having made all reasonable enquiries, as at the date of this announcement, DOBOT is an independent third party and not a connected person of the Company.

**Shareholders of the Company and potential investors should note that this announcement is made on a voluntary disclosure basis for the purpose of keeping the public informed of the latest business developments of the Company. The Company will make further announcement (where applicable) in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.**

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Company's shares.**

By order of the Board  
**YSB Inc.**  
**Mr. Buzhen Zhang**  
*Chairman and executive Director*

Hong Kong, 3 June 2025

*As of the date of this announcement, the Board comprises Mr. Buzhen Zhang and Mr. Fei Chen as executive Directors, Mr. Ziyang Zhu as non-executive Director, and Ms. Rong Shao, Mr. Sam Hanhui Sun and Mr. Hongqiang Zhao as independent non-executive Directors.*